Day: February 6, 2024

Pilot Plant Construction Commences with Anticipated Q2 2024 Commissioning MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY), a high-tech company (the “Company” or “PyroGenesis”) that designs, develops, manufactures and commercializes advanced plasma processes and sustainable solutions which are geared to reduce greenhouse gases (GHG) and address environmental pollutants, is pleased to announce that, further to HPQ Silicon Inc’s (“HPQ” or the “Client”) press release dated today, and the Company’s own news releases dated November 9, 2023 and January 11, 2024, the next milestone for pilot plant development has been reached. The Fumed Silica Reactor (FSR) technology project is being conducted in conjunction with HPQ Silica Polvere Inc. (“HPQ Polvere”), a...

MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its fourth quarter and full year fiscal 2023 ended November 30, on Wednesday, February 21, 2024, at 8:30 a.m. EDT. Theratechnologies will also provide further information on the Complete Response Letter issued by the U.S. Food and Drug Administration in response to the Company’s supplemental Biologics License Application for the F8 formulation of tesamorelin. The call will be hosted by Mr. Paul Lévesque, President and Chief Executive Officer. Mr. Lévesque will be joined by other members of the management team,...

CELEBRATION, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that it will present at the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference being held virtually on Tuesday, February 13, 2024, at 9:20 a.m. ET. Additionally, members of Zevra’s management team will be available for one-on-one investor meetings with registered attendees during the conference from February 13-14, 2024. The live webcast will be available here. Following Zevra’s presentation, the archived presentation will be accessible under “Events & Presentations” on the Investor Relations section of Zevra’s website at investors.zevra.com. To register for the conference, contact your Oppenheimer sales representative. About Zevra Therapeutics:  Zevra...

TROY, Mich, Feb. 06, 2024 (GLOBE NEWSWIRE) — Agrify Corporation (Nasdaq: AGFY) (“Agrify” or the “Company”), a leading provider of innovative cultivation and extraction solutions for the cannabis industry, today announced the successful installation of a PX-30 Hydrocarbon Extraction System at its customer’s Michigan facility. The PX-30 Hydrocarbon Extraction System is the largest system of Agrify’s PX-Extraction series, and represents a cutting-edge advancement in hydrocarbon extraction technology, designed to enhance efficiency and precision in the extraction process. This installation marks a significant milestone for Agrify, reinforcing the company’s commitment to delivering state-of-the-art solutions to the cannabis and hemp industries as operators around the country continue to purchase and operate with Agrify’s latest technologies. Lume...

MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) — HPQ Silicon Inc. (“HPQ” or the “Company”) (TSX-V: HPQ) (OTCQB: HPQFF) (FRA: O08), a technology company specializing in green engineering of silica and silicon-based materials, is pleased to update shareholders on a new milestone related to its Fumed Silica Reactor (FSR) Pilot Plant project. HPQ Silicon’s wholly owned subsidiary, HPQ Silica Polvere Inc. (HPQ Polvere), received notification from its technology provider and equipment supplier, PyroGenesis Canada Inc. (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY) (PyroGenesis), that the engineering design for the FSR Pilot Plant project has been concluded. All equipment parts needed for the project have been sourced, fabrication is completed, and all additional peripheral materials have been ordered. SCALING UP HPQ’S FUMED SILICA REACTOR The ability...

Ivanhoe Electric Drills 348m of 1.08 g/t AuEq Containing 0.43 g/t Gold, 40.48 g/t Silver, 0.22% Lead, and 0.12% Zinc Including 1m of 36.94 g/t AuEq Containing 2180 g/t Silver, 5.16 g/t Gold, 0.63% Copper, 6.00% Lead, 6.14% Zinc VANCOUVER, British Columbia, Feb. 06, 2024 (GLOBE NEWSWIRE) — Brixton Metals Corporation (TSX-V: BBB, OTCQB: BBBXF) (the “Company” or “Brixton”) is pleased to announce additional results from the 2023 Exploration Program on the Hog Heaven Project, which is currently being operated under a definitive Earn-in Agreement with Ivanhoe Electric Inc. (see news release dated March 2nd, 2021). Ivanhoe Electric holds the option to acquire up to 75% interest by completing USD$40 million of project spending and paying Brixton USD$4.5 million. Hog Heaven is an advanced-stage, high-sulphidation, epithermal copper-silver-gold...

DETROIT, Feb. 06, 2024 (GLOBE NEWSWIRE) — Amesite Inc. (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform for business and education markets, announces aggregate retention numbers for users enrolled in programs delivered on its technology stack, and its growing sales activity. Amesite reports an overall retention rate (the percentage of enrollees that remain in a course) of 98% for paid learning experiences on its platform. These results overwhelmingly exceed industry norms. On average, online retention rates for paid online courses are only between 68-73%. Amesite retentions in specific categories follow:96% retention for technology upskilling programs, such as data science or electric vehicle technologies 98% retention for professional development programs, such as implicit...

United Healthcare Updated Medical Policy Favoring Oral Appliance Therapies and Recent Recalls of Many ResMed and Philips Respironics’ CPAP Devices Create Significant Revenue Opportunities for Vivos Devices LITTLETON, Colo., Feb. 06, 2024 (GLOBE NEWSWIRE) — Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA)) in adult patients, today highlighted certain significant favorable market developments creating new opportunities to widen its funnel of potential users of Vivos’ oral appliance therapies. On November 2, 2023, the U.S. Food and Drug Administration (FDA) granted, for...